Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction (Nerve-RESTORE℠)

15 de junho de 2026 atualizado por: Axogen Corporation
This is a multicenter, 1:1 randomized, prospective, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Visão geral do estudo

Descrição detalhada

This is a multicenter, 1:1 randomized, prospective, evaluator blinded, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. The study will assess recovery of motor and sensory function via MRCC score for nerve repairs with Avance Nerve Graft (Study Treatment) and sural nerve autograft (Comparator) through non-inferiority analyses. Participants will be considered enrolled to the study once all screening and eligibility criteria have been met and the participant has been centrally randomized to either Avance Nerve Graft or sural nerve autograft; Inclusion and exclusion criteria are defined at decision points for pre-operative screening eligibility and operative eligibility. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Tipo de estudo

Intervencional

Inscrição (Estimado)

178

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Recrutamento
        • OrthoIndy
        • Contato:
        • Investigador principal:
          • Brandon Smetana, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Study Participant Criteria

  1. Be ≥ 18 years of age at the time of consent;
  2. Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration;
  3. Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures;

    Injury/Repair Criteria for Each Nerve

  4. Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s):

    • Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow;
    • Anterior interosseous nerve;
    • Median nerve recurrent motor branch;
    • Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus;
    • Posterior interosseous nerve.
  5. Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4;
  6. In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft;
  7. Measured nerve gap(s) following resection > 25 mm;
  8. Nerve(s) repaired ≤ 120 days post injury;
  9. Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and
  10. Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve[s] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types).

Exclusion Criteria:

Study Participant Criteria

  1. Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study;
  2. Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s);
  3. History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb;
  4. History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease);
  5. History of chronic ischemic condition of the upper extremity;
  6. Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy;
  7. Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems;
  8. Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule;

    Injury/Repair Criteria for Each Nerve

  9. Median nerve repairs where the ulnar nerve has been transected due to injury or repair;
  10. Repair(s) of a sensory-only proximal nerve stump;
  11. Incomplete nerve transections;
  12. Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target);
  13. Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment;
  14. Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve;
  15. Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s);
  16. Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques;
  17. Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ;
  18. Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and
  19. Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured [one injured artery is allowed]).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Avance Nerve Graft
Study Treatment: Avance Nerve Graft repairs of mixed or motor nerves (> 25 mm gaps)
A commercially available, sterile, single-use peripheral nerve scaffold indicated for the treatment of functional deficits, manufactured from decellularized and sterilized extracellular matrix derived from human peripheral nerve tissue.
Outros nomes:
  • Acellular nerve allograft-arwx
Comparador Ativo: Sural nerve autograft
Comparator: Sural nerve autograft repairs of mixed or motor nerves (> 25 mm gaps)
A patient's own peripheral nerve tissue harvested in a secondary surgical procedure of the lower extremity where a functioning sural nerve is sacrificed for use in the reconstruction of a nerve defect.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Recovery of motor function
Prazo: Assessed at 24 months
Medical Research Council Classification (MRCC) of motor recovery score. This is an ordinal scale from M0-M5, with grade M0 meaning no contraction and M5 meaning full recovery in all muscles.
Assessed at 24 months
Recovery of sensory function
Prazo: Assessed at 24 months
Medical Research Council Classification (MRCC) of sensory recovery score. This is an ordinal scale from S0-S4, with grade S0 meaning absence of sensibility in the autonomous area and S4 meaning complete recovery (2-point discrimination, 2-6 mm).
Assessed at 24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Meaningful recovery (MR) of motor and sensory function
Prazo: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Medical Research Council Classification (MRCC) of motor recovery score. Meaningful recovery is defined as ≥ M3 MRCC of motor recovery and ≥ S3 MRCC of sensory recovery.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Treatment response (TR) of motor and sensory function
Prazo: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Medical Research Council Classification (MRCC) of motor recovery score. Treatment response is defined as a 1-point increase in MRCC score from post-operative baseline.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time to MR of motor and sensory function
Prazo: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time from surgery to meaningful recovery of motor function in all repairs and of sensory function in mixed nerve repairs.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time to TR of motor and sensory function
Prazo: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time from surgery to treatment response of motor function in all repairs and of sensory function in mixed nerve repairs.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
QuickDASH upper extremity disability score
Prazo: Assessed at 24 months
The QuickDASH questionnaire (including Work and Sports/Performance Art modules if applicable) is a PROM questionnaire to measure physical functions and symptoms in participants with upper limb musculoskeletal disorders and will be used to assess the study participant's functional quality of life (QoL)as it pertains to the affected arm. This 11-item questionnaire addresses arm-specific symptoms and disability during the preceding week and is used to estimate the participant's view of disability. Each item is based on an ordinal scale from 1 to 5, where higher values are worse. QuickDASH scores range from 0 to 100, with a score of 0 indicating no disability and a score of 100 representing the most severe disability.
Assessed at 24 months
Lower Extremity Functional Scale (LEFS) score
Prazo: Assessed at 24 months
The LEFS is a valid and reliable assessment for documenting function for individuals and groups with injury or disability to the lower extremity. It is based on the World Health Organization's model of disability and handicap and is applicable to a wide variety of participants with lower extremity orthopedic conditions, including participants with a range of disability levels, conditions, diseases, treatments, and ages. Applicable to sural nerve autograft group only. The LEFS consists of 20 questions, with each activity rated from 0 (extremely difficult or unable) to 4 (no difficulty). Scores range from 0 to 80, where higher scores indicate better lower limb function.
Assessed at 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: R. Glenn Gaston, MD, OrthoCarolina Research Institute, Inc.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

12 de junho de 2026

Conclusão Primária (Estimado)

5 de dezembro de 2030

Conclusão do estudo (Estimado)

5 de dezembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

15 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de junho de 2026

Primeira postagem (Real)

18 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Lesão do Nervo Periférico

Ensaios clínicos em Avance Nerve Graft

Se inscrever